Protect Medical Device Implants Against Oxidative Damage


Oxidation Resistant Bioprosthetic Tissues


Market Need


Over 200,000 patients worldwide receive bioprosthetic heart valves. Compared to mechanical valves, bioprosthetics do not require patient anti-coagulation treatment. Although the risk of thromboembolism is significantly reduced, bioprosthetic valves demonstrate poor durability. Structural deterioration results in reoperations in more than a quarter of patients. Aside from failure due to accumulation of calcium deposits on the valve surface, other factors impacting durability remain poorly understood.


Technology Overview


Dr. Robert Levy and his team identified reactive oxygen species (ROS) as potential contributors to the structural damage of bioprosthetic heart valves. By covalently attaching antioxidant molecules to heterograft tissue, the treated bioprosthetic can prevent oxidative degradation. Using bovine pericardium tissue ex vivo, researchers demonstrated that attaching anti-oxidant DBP-amine reduces ROS activity and mitigates the breakdown of the bioprosthetic tissue.



•       Improves valve durability in the presence of reactive oxygen species (ROS)


•       Method extends to many bioprosthetic materials


Stage of Development: Ex vivo proof of concept


Case ID:
Web Published:
Patent Information:
Title Country Serial No. Patent No. File Date Issued Date
Oxidation Resistant Bioprosthetic Tissues and Preparation Thereof Australia 2012282660 2012282660 7/11/2012 11/9/2017
Oxidation Resistant Bioprosthetic Tissues and Preparation Thereof United States 14/232,005 10,058,419 7/11/2012 8/28/2018
For Information, Contact:
Simone Temporal
Licensing Associate
The Children's Hospital of Philadelphia
Robert Levy
Ivan Alferiev
Stanley Stachelek
Jeanne Connolly
Abigail Christian